{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T17:22:53Z","timestamp":1794417773257,"version":"4.9.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Primary mediastinal large B-cell lymphoma (PMBCL) predominantly affects female adolescents and young adults. It displays an immune-privileged phenotype and demonstrates the involvement of key cytokine signaling pathways, including increased expression of thymus- and activation-regulated chemokine (TARC\/CC chemokine ligand 17 [CCL17]). Currently, there is a lack of established markers for stratification. We studied plasma concentrations of 24 cytokines at diagnosis in a large population\u2013based pediatric cohort of 62 patients with PMBCL. Compared with a group of age-matched patients with other types of lymphomas in long-term remission and healthy individuals (n = 26), patients with PMBCL showed elevated concentrations of CCL4, CCL17, interleukin-6 (IL-6), CXC chemokine ligand 8 (CXCL8), CXCL9, CXCL10, and CXCL11. The median CCL17 level was 1695 pg\/mL (interquartile range [IQR], 642-3142) in patients with PMBCL compared with 81 pg\/mL (IQR, 41-190) in controls (P&amp;lt; .0001). The concentrations of CCL17, CXCL9, and CXCL10 significantly correlated with mediastinal tumor volume (MTV) and lactate dehydrogenase (LDH) activity but were not associated with event-free survival (EFS). The concentrations of IL-17F and IL-22 were inversely correlated with LDH activity and MTV. Elevated IL-6, IL-10, IL-17A, and IL-22 levels were significantly correlated with inferior EFS in a subgroup of 50 patients uniformly treated with dose-adjusted (DA)-EPOCH-R (etoposide, prednisone, oncovin [vincristine], cyclophosphamide, doxorubicin, and rituximab). Although based on a limited number of events, IL-6 level showed the strongest association with outcome (hazard ratio, 6.8; 95% confidence interval, 1.5-30.9). In summary, pretreatment cytokine levels in patients with PMBCL reveal distinct patterns associated with tumor burden (CCL17, CXCL9, and CXCL10) and outcome (IL-6, IL-10, IL-17A, and IL-22).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026021463","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:54:58Z","timestamp":1789073698000},"page":"7525-7535","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Cytokine concentrations in pediatric primary mediastinal large B-cell lymphoma correlate with disease extent and outcome"],"prefix":"10.1182","volume":"10","author":[{"given":"Malte","family":"Nipper","sequence":"first","affiliation":[{"name":"1Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"2Research Institute Children's Cancer Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damm-Welk","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"2Research Institute Children's Cancer Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5630-8505","authenticated-orcid":false,"given":"Will","family":"Shepheard","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"2Research Institute Children's Cancer Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilske","family":"Oschlies","sequence":"additional","affiliation":[{"name":"3Section for Hematopathology and Lymph Node Registry, Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"3Section for Hematopathology and Lymph Node Registry, Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-829X","authenticated-orcid":false,"given":"Birgit","family":"Burkhardt","sequence":"additional","affiliation":[{"name":"4Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Woessmann","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"2Research Institute Children's Cancer Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1831-3702","authenticated-orcid":false,"given":"Fabian","family":"Kn\u00f6rr","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology and Oncology and NHL-BFM Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"2Research Institute Children's Cancer Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026111111215673000_bib1","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2026111111215673000_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood-2003-10-3545","article-title":"Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma","volume":"104","author":"Guiter","year":"2004","journal-title":"Blood"},{"issue":"26","key":"2026111111215673000_bib3","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2026111111215673000_bib4","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma","volume":"19","author":"Marri","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026111111215673000_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ajh.23259","article-title":"Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients","volume":"87","author":"Ansell","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"2026111111215673000_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2017.177972","article-title":"Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"103","author":"Kn\u00f6rr","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2026111111215673000_bib7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.1997.15.4.1646","article-title":"Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients","volume":"15","author":"Lazzarino","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026111111215673000_bib8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2004-12-4901","article-title":"NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes","volume":"106","author":"Feuerhake","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2026111111215673000_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.23.01053","article-title":"Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes","volume":"42","author":"Noerenberg","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026111111215673000_bib10","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood-2004-09-3701","article-title":"Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line","volume":"105","author":"Melzner","year":"2005","journal-title":"Blood"},{"issue":"18","key":"2026111111215673000_bib11","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","article-title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","volume":"131","author":"Vigan\u00f2","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2026111111215673000_bib12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood.2025028412","article-title":"Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma","volume":"146","author":"Rai","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026111111215673000_bib13","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma","volume":"154","author":"Van den Berg","year":"1999","journal-title":"Am J Pathol"},{"issue":"7","key":"2026111111215673000_bib14","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1002\/hem3.117","article-title":"NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker","volume":"8","author":"Kroeze","year":"2024","journal-title":"Hemasphere"},{"issue":"23","key":"2026111111215673000_bib15","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/blood.2025028823","article-title":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial","volume":"146","author":"Zucca","year":"2025","journal-title":"Blood"},{"issue":"5","key":"2026111111215673000_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2026111111215673000_bib17","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3324\/haematol.2021.278971","article-title":"Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma","volume":"106","author":"Kn\u00f6rr","year":"2021","journal-title":"Haematologica"},{"issue":"33","key":"2026111111215673000_bib18","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.21.00920","article-title":"Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial","volume":"39","author":"Burke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026111111215673000_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj030","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience","volume":"17","author":"Savage","year":"2006","journal-title":"Ann Oncol"},{"issue":"12","key":"2026111111215673000_bib20","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/bloodadvances.2025019553","article-title":"Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R","volume":"10","author":"Meyer-Wentrup","year":"2026","journal-title":"Blood Adv"},{"issue":"8","key":"2026111111215673000_bib21","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"2026111111215673000_bib22","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026111111215673000_bib23","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"issue":"18","key":"2026111111215673000_bib24","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026111111215673000_bib25","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3324\/haematol.2023.283446","article-title":"Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients","volume":"109","author":"Cook","year":"2024","journal-title":"Haematologica"},{"issue":"18","key":"2026111111215673000_bib26","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2025015837","article-title":"Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma","volume":"9","author":"Teesink","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"2026111111215673000_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"2026111111215673000_bib28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.194.6.847","article-title":"Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and Ccr8 by Cd4+Cd25+ regulatory T cells","volume":"194","author":"Iellem","year":"2001","journal-title":"J Exp Med"},{"issue":"2","key":"2026111111215673000_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/blood-2010-05-285908","article-title":"A novel role for IL-22R1 as a driver of inflammation","volume":"117","author":"Savan","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2026111111215673000_bib30","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2026111111215673000_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1008301602785","article-title":"Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival","volume":"10","author":"Sarris","year":"1999","journal-title":"Ann Oncol"},{"issue":"3","key":"2026111111215673000_bib32","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cyto.2012.08.028","article-title":"Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study","volume":"60","author":"Charbonneau","year":"2012","journal-title":"Cytokine"},{"issue":"12","key":"2026111111215673000_bib33","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2026111111215673000_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer cell"},{"issue":"4","key":"2026111111215673000_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1098-2264(2001)9999:9999<::AID-GCC1105>3.0.CO;2-I","article-title":"Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line","volume":"30","author":"Bentz","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"2026111111215673000_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","article-title":"Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up","volume":"10","author":"Zhou","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026111111215673000_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"2026111111215673000_bib38","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1073\/pnas.0603507103","article-title":"Nucleophosmin\/anaplastic lymphoma kinase (NPM\/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3","volume":"103","author":"Kasprzycka","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026111111215673000_bib39","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-\u03baB pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"issue":"17","key":"2026111111215673000_bib40","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1007\/s00018-010-0380-0","article-title":"Structure and function of interleukin-22 and other members of the interleukin-10 family","volume":"67","author":"Trivella","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"2026111111215673000_bib41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2026111111215673000_bib42","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2026111111215673000_bib43","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1038\/s41467-018-06134-z","article-title":"STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas","volume":"9","author":"Pan","year":"2018","journal-title":"Nat Commun"},{"issue":"52","key":"2026111111215673000_bib44","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026111111215673000_bib45","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026111111215673000_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"issue":"7","key":"2026111111215673000_bib47","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1084\/jem.20090207","article-title":"IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway","volume":"206","author":"Wang","year":"2009","journal-title":"J Exp Med"},{"issue":"6","key":"2026111111215673000_bib48","doi-asserted-by":"crossref","first-page":"e39228","DOI":"10.1371\/journal.pone.0039228","article-title":"A simple method to quantitate IP-10 in dried blood and plasma spots","volume":"7","author":"Aabye","year":"2012","journal-title":"PloS one"},{"issue":"4","key":"2026111111215673000_bib49","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/bjh.70095","article-title":"Interferon-gamma and C-X-C motif chemokine ligand 9, which is better for haemophagocytic lymphohistiocytosis diagnosis and monitoring?","volume":"207","author":"Luo","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"2026111111215673000_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hon.3096","article-title":"Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era","volume":"41","author":"Vassilakopoulos","year":"2023","journal-title":"Hematol Oncol"},{"issue":"3","key":"2026111111215673000_bib51","first-page":"1111","article-title":"Utility of the central nervous System international prognostic index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy","volume":"111","author":"Yang","year":"2026","journal-title":"Haematologica"},{"issue":"12","key":"2026111111215673000_bib52","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.4049\/jimmunol.181.12.8391","article-title":"CCR6 regulates the migration of inflammatory and regulatory T cells","volume":"181","author":"Yamazaki","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"2026111111215673000_bib53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","article-title":"Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells","volume":"173","author":"Baumforth","year":"2008","journal-title":"Am J Pathol"},{"issue":"3-4","key":"2026111111215673000_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.mn.7800198","article-title":"Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense","volume":"10","author":"Gear","year":"2003","journal-title":"Microcirculation"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7525\/2599788\/blooda_adv-2026-021463-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7525\/2599788\/blooda_adv-2026-021463-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:22:09Z","timestamp":1794414129000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7525\/570891\/Cytokine-concentrations-in-pediatric-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":54,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021463","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}